Industry
Since our separation, GE HealthCare has become intensely focused on patients and patient outcomes, and innovative technology is an important part of that.
We have declared our goal to make all our production facilities globally carbon neutral by 2035 and have launched over 100 initiatives to achieve this.
We have established a dedicated thermal management team and are set to launch a new product line aimed at improving data center energy efficiency. This initiative involves innovative cooling solutions that involve immersing servers in specially designed fluids to dissipate heat more effectively, thus reducing the massive energy consumption typically associated with cooling systems.
The emphasis on carbon neutrality and the practical application of carbon pricing in project assessments demonstrate Kuraray's proactive stance in balancing economic viability with environmental responsibility.
We saw the chance to disrupt the lengthy and costly process of bringing therapeutics from discovery to patient by offering innovative services and leveraging our R&D capabilities.
Our OneSource services offering exemplifies how AI can optimize operations within biopharma R&D labs. By relieving scientists from the burdens of instrument complexity and maintenance, we enable them to focus on their primary objective: drug development.
Our goal is to significantly expand access to CAVT so patients are able to get more advanced treatment quickly, potentially resulting in better care.
Our technologies are also pivotal in public health, illustrated by their use in combating the spread of COVID-19 through sanitization. This example highlights the indispensable role of microbial control in maintaining the quality and safety of numerous aspects of our daily environment.
Verily Viewpoint is part of our comprehensive suite for enhancing clinical research, including partnerships with biopharmaceutical companies to optimize clinical trials through technology. This encompasses patient recruitment, consent processes, and clinical trial management.
Immunovant has attracted significant attention and investment from the market, highlighted by a $200 million investment from Roivant Sciences in August of 2021 and a $450 million capital raise in October of 2023.
